세계의 섬유낭성 유방 질환 시장 보고서(2025년)

Fibrocystic Breast Condition Global Market Report 2025

US $ 4,490 ￦ 6,183,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,938,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,692,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

섬유낭성 유방 질환 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 6.1%로 성장할 전망이며, 91억 달러로 성장이 예측됩니다. 예측 기간 중의 성장은 진단 툴 및 치료에 대한 수요 증가, 정부 조성금 증가, 효과적인 치료에 대한 요구 고조, 고령자 인구 확대, 관민 기관에 의한 대처, 연구 개발 활동의 활발화 등에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 저침습성 유방 생검장치 채택, 전략적 파트너십 및 제휴, 맞춤형 의료 중시, 인공지능(AI) 통합, 지속적인 기술 진보 등이 있습니다.

유방암 유병률 증가는 섬유낭성 유방 질환 시장의 성장을 가속할 것으로 예측됩니다. 유방암은 유방 세포에 발생하는 암의 일종으로, 주로 여성이 이환합니다. 고령화, 건강하지 못한 라이프 스타일, 유전적 소인, 검진 증가, 환경 폭로 등의 요인이 발생률 상승에 기여하고 있습니다. 섬유낭성 유방 질환(FBC)은 유선 조직을 조밀하게 함으로써 유방암 위험을 상승시킬 수 있으며, 그 결과 세포의 변화, 호르몬 감수성 항진, 염증의 장기화 등이 촉진되어 암 개발을 촉진하는 환경을 만들어 낼 수 있습니다. 예를 들어 2024년 7월 미국암협회 Facts and Figures는 미국의 새로운 유방암 사례 수가 2023년 30만 590례에서 2024년 31만 3,510례로 증가한 것으로 평가됐다고 보고했습니다. 그 결과 유방암 유병률 증가가 섬유낭성 유방 질환 시장 확대에 기여하고 있습니다.

원격 의료 서비스 증가도 섬유낭성 유방 질환 시장의 성장에 기여하고 있습니다. 원격 의료 서비스는 화상 통화, 모바일 애플리케이션, 온라인 플랫폼 등의 디지털 통신 기술을 이용하여 원격 의료 상담, 진단, 치료를 제공합니다. 원격의료 확대는 디지털 헬스 플랫폼 채택 확대, 인터넷 접근성 개선, 원격 헬스케어 서비스에 대한 환자 선호에 의해 추진되고 있습니다. 섬유낭성 유방 질환을 가진 환자에게 원격의료는 원격진료, 시기적절한 증상관리, 전문가 의료지도를 가능하게 하여 대면진료의 필요성을 줄이고 환자의 편의성을 높입니다. 예를 들어 2023년 2월 미국에 본사를 둔 록헬스는 2022년 조사에서 응답자의 80%가 원격의료 서비스를 이용한 적이 있다고 보고했으며, 이는 2021년 72%에서 8% 포인트 증가한 것을 반영하고 있습니다. 이러한 원격의료 접근성 증가는 섬유낭성 유방 질환 시장 확대에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 섬유낭성 유방 질환 시장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 섬유낭성 유방 질환 시장 : 성장률 분석
• 세계의 섬유낭성 유방 질환 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 섬유낭성 유방 질환 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 섬유낭성 유방 질환 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 섬유낭성 유방 질환 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 약
• 경구 피임약
• 세침 흡인법
• 기타
• 세계의 섬유낭성 유방 질환 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 유방 조영
• 초음파
• 임상 유방 검사
• 기타
• 세계의 섬유낭성 유방 질환 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 기타
• 세계의 섬유낭성 유방 질환 시장 : 약제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 시판되는 진통제
• 처방 진통제
• 호르몬 요법
• 세계의 섬유낭성 유방 질환 시장 : 경구 피임약 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 배합정
• 프로게스틴만의 알약
• 세계의 섬유낭성 유방 질환 시장 : 세침 흡인법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 초음파 가이드 하세침 흡인법
• 수동 세침 흡인법
• 세계의 섬유낭성 유방 질환 시장 : 기타 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 라이프 스타일 및 식생활 변화
• 낭포 배수 처리
• 지지요법
• 허브 및 영양 보조 식품

제7장 지역별 및 국가별 분석

• 세계의 섬유낭성 유방 질환 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 섬유낭성 유방 질환 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 섬유낭성 유방 질환 시장 : 경쟁 구도
• 섬유낭성 유방 질환 시장 : 기업 프로파일
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Hitachi Medical Systems : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Roche Diagnostics : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Sanofi SA
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Siemens Healthineers AG
• Fujifilm Holdings Corporation
• Philips Healthcare
• Becton Dickinson and Company
• GE Healthcare Technologies Inc.
• Teva Pharmaceutical Industries Ltd
• Hologic Inc.
• Canon Medical Systems Corporation
• Hikma Pharmaceuticals plc
• Steris Pharma
• Lannett Company Inc.

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 섬유낭성 유방 질환 시장(2029년) : 새로운 기회를 제공하는 국가
• 섬유낭성 유방 질환 시장(2029년) : 새로운 기회를 제공하는 부문
• 섬유낭성 유방 질환 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Fibrocystic breast condition (FBC) is a noncancerous disorder marked by lumpiness, tenderness, and pain in one or both breasts due to the presence of fibrous tissue and fluid-filled cysts. This common benign breast condition is primarily linked to hormonal fluctuations and mostly affects women of reproductive age. Symptoms often change throughout the menstrual cycle and usually subside after menopause.

Treatment options for fibrocystic breast condition include medications, oral contraceptives, fine-needle aspiration, and other approaches. Medications, such as over-the-counter pain relievers or hormonal therapies in severe cases, help alleviate pain and tenderness. Diagnosis involves various methods, including mammograms, ultrasounds, clinical breast exams, and other diagnostic techniques. The condition is managed in different healthcare settings, including hospitals, clinics, and other medical facilities.

The fibrocystic breast condition market research report is one of a series of new reports from The Business Research Company that provides fibrocystic breast condition market statistics, including the fibrocystic breast condition industry global market size, regional shares, competitors with the fibrocystic breast condition market share, detailed fibrocystic breast condition market segments, market trends, and opportunities, and any further data you may need to thrive in the fibrocystic breast condition industry. This fibrocystic breast condition market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibrocystic breast condition market size has grown strongly in recent years. It will grow from $6.74 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historical period can be attributed to the increasing prevalence of breast cancer, higher healthcare expenditure, urbanization, greater awareness, lifestyle changes, and elevated disposable income.

The fibrocystic breast condition market size is expected to see strong growth in the next few years. It will grow to $9.10 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to the increasing demand for diagnostic tools and treatments, rising government funding, growing need for effective therapies, an expanding geriatric population, initiatives by public and private organizations, and heightened research and development activities. Key trends expected in this period include the adoption of minimally invasive breast biopsy devices, strategic partnerships and collaborations, a greater emphasis on personalized medicine, the integration of artificial intelligence (AI), and continuous technological advancements.

The increasing prevalence of breast cancer is expected to drive the growth of the fibrocystic breast condition market. Breast cancer is a type of cancer that originates in the cells of the breast and primarily affects women. Factors such as an aging population, unhealthy lifestyles, genetic predisposition, increased screening, and environmental exposures contribute to its rising occurrence. Fibrocystic breast condition (FBC) may elevate the risk of breast cancer by leading to dense breast tissue, which can promote cellular changes, heightened hormone sensitivity, and prolonged inflammation, creating an environment that may facilitate cancer development. For example, in July 2024, the American Cancer Society Facts and Figures reported that the number of new breast cancer cases in the United States is expected to rise from 300,590 in 2023 to 313,510 in 2024. As a result, the growing prevalence of breast cancer is fueling the expansion of the fibrocystic breast condition market.

The increasing availability of telemedicine services is contributing to the growth of the fibrocystic breast condition market. Telemedicine services utilize digital communication technologies, such as video calls, mobile applications, and online platforms, to provide remote medical consultations, diagnosis, and treatment. The expansion of telemedicine is driven by the growing adoption of digital health platforms, improved internet accessibility, and patient preferences for remote healthcare services. For individuals with fibrocystic breast condition, telemedicine enables remote consultations, timely symptom management, and expert medical guidance, reducing the necessity for in-person visits and enhancing patient convenience. For instance, in February 2023, Rock Health, a US-based corporation, reported that 80% of respondents in its 2022 survey had used telemedicine services at some point, reflecting an 8 percentage point increase from 72% in 2021. This increased access to telemedicine is contributing to the expansion of the fibrocystic breast condition market.

Leading companies in the fibrocystic breast condition market are developing advanced diagnostic technologies to enhance diagnostic accuracy and treatment outcomes. Diagnostic devices are tools used to detect, identify, or assess medical conditions and diseases. In August 2024, Izotropic Corporation, a Canada-based medical device company, introduced IzoView, a breast CT imaging system designed to improve breast cancer diagnosis in women with dense breast tissue. The company is seeking regulatory approval through a clinical study aimed at demonstrating the superior diagnostic performance of IzoView when used alongside digital breast tomosynthesis (DBT) compared to DBT alone. With high-resolution 3D imaging capabilities and the advantage of eliminating the need for breast compression, IzoView aims to enhance breast cancer detection rates in women with dense breast tissue, a group at higher risk for developing the disease.

Major players in the fibrocystic breast condition market are Pfizer Inc., Hitachi Medical Systems, Roche Diagnostics, Merck & Co Inc., Bayer AG, Sanofi SA, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Fujifilm Holdings Corporation, Philips Healthcare, Becton Dickinson and Company, GE Healthcare Technologies Inc., Teva Pharmaceutical Industries Ltd, Hologic Inc., Canon Medical Systems Corporation, Hikma Pharmaceuticals plc, Steris Pharma, Lannett Company Inc., Argon Medical Devices Inc., and AdvaCare Pharma USA LLC.

North America was the largest region in the fibrocystic breast condition market in 2024. The regions covered in fibrocystic breast condition report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fibrocystic breast condition market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibrocystic breast condition market consists of revenues earned by entities by providing services such as diagnosis and screening services, surgical interventions, healthcare consultations and follow-ups, medical treatments, and medications. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibrocystic breast condition market also includes sales of hormonal therapies, ultrasound devices, cyst aspiration kits, vitamins, and supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibrocystic Breast Condition Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fibrocystic breast condition market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fibrocystic breast condition ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibrocystic breast condition market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Oral Contraceptives; Fine-Needle Aspiration; Other Treatments
• 2) By Diagnosis: Mammogram; Ultrasound; Clinical Breast Exam; Other Diagnosis
• 3) By End-Users: Hospital; Clinic; Other End-Users
• Subsegments:
• 1) By Medication: Over-the-Counter (OTC) Pain Relievers; Prescription Pain Relievers; Hormonal Therapy
• 2) By Oral Contraceptives: Combination Pills; Progestin-Only Pills
• 3) By Fine-Needle Aspiration: Ultrasound-Guided Fine-Needle Aspiration; Manual Fine-Needle Aspiration
• 4) By Other Treatments: Lifestyle And Dietary Changes; Cyst Drainage Procedures; Supportive Therapy; Herbal And Dietary Supplements
• Companies Mentioned: Pfizer Inc.; Hitachi Medical Systems; Roche Diagnostics; Merck & Co Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fibrocystic Breast Condition Market Characteristics

3. Fibrocystic Breast Condition Market Trends And Strategies

4. Fibrocystic Breast Condition Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Fibrocystic Breast Condition Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fibrocystic Breast Condition PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fibrocystic Breast Condition Market Growth Rate Analysis
• 5.4. Global Fibrocystic Breast Condition Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fibrocystic Breast Condition Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fibrocystic Breast Condition Total Addressable Market (TAM)

6. Fibrocystic Breast Condition Market Segmentation

• 6.1. Global Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Oral Contraceptives
• Fine-Needle Aspiration
• Other Treatment
• 6.2. Global Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammogram
• Ultrasound
• Clinical Breast Exam
• Other Diagnosis
• 6.3. Global Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Other End-Users
• 6.4. Global Fibrocystic Breast Condition Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Over-the-Counter (OTC) Pain Relievers
• Prescription Pain Relievers
• Hormonal Therapy
• 6.5. Global Fibrocystic Breast Condition Market, Sub-Segmentation Of Oral Contraceptives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Pills
• Progestin-Only Pills
• 6.6. Global Fibrocystic Breast Condition Market, Sub-Segmentation Of Fine-Needle Aspiration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ultrasound-Guided Fine-Needle Aspiration
• Manual Fine-Needle Aspiration
• 6.7. Global Fibrocystic Breast Condition Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lifestyle And Dietary Changes
• Cyst Drainage Procedures
• Supportive Therapy
• Herbal And Dietary Supplements

7. Fibrocystic Breast Condition Market Regional And Country Analysis

• 7.1. Global Fibrocystic Breast Condition Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fibrocystic Breast Condition Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fibrocystic Breast Condition Market

• 8.1. Asia-Pacific Fibrocystic Breast Condition Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fibrocystic Breast Condition Market

• 9.1. China Fibrocystic Breast Condition Market Overview
• 9.2. China Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fibrocystic Breast Condition Market

• 10.1. India Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fibrocystic Breast Condition Market

• 11.1. Japan Fibrocystic Breast Condition Market Overview
• 11.2. Japan Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fibrocystic Breast Condition Market

• 12.1. Australia Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fibrocystic Breast Condition Market

• 13.1. Indonesia Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fibrocystic Breast Condition Market

• 14.1. South Korea Fibrocystic Breast Condition Market Overview
• 14.2. South Korea Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fibrocystic Breast Condition Market

• 15.1. Western Europe Fibrocystic Breast Condition Market Overview
• 15.2. Western Europe Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fibrocystic Breast Condition Market

• 16.1. UK Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fibrocystic Breast Condition Market

• 17.1. Germany Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fibrocystic Breast Condition Market

• 18.1. France Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fibrocystic Breast Condition Market

• 19.1. Italy Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fibrocystic Breast Condition Market

• 20.1. Spain Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fibrocystic Breast Condition Market

• 21.1. Eastern Europe Fibrocystic Breast Condition Market Overview
• 21.2. Eastern Europe Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fibrocystic Breast Condition Market

• 22.1. Russia Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fibrocystic Breast Condition Market

• 23.1. North America Fibrocystic Breast Condition Market Overview
• 23.2. North America Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fibrocystic Breast Condition Market

• 24.1. USA Fibrocystic Breast Condition Market Overview
• 24.2. USA Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fibrocystic Breast Condition Market

• 25.1. Canada Fibrocystic Breast Condition Market Overview
• 25.2. Canada Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fibrocystic Breast Condition Market

• 26.1. South America Fibrocystic Breast Condition Market Overview
• 26.2. South America Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fibrocystic Breast Condition Market

• 27.1. Brazil Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fibrocystic Breast Condition Market

• 28.1. Middle East Fibrocystic Breast Condition Market Overview
• 28.2. Middle East Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fibrocystic Breast Condition Market

• 29.1. Africa Fibrocystic Breast Condition Market Overview
• 29.2. Africa Fibrocystic Breast Condition Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fibrocystic Breast Condition Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fibrocystic Breast Condition Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fibrocystic Breast Condition Market Competitive Landscape And Company Profiles

• 30.1. Fibrocystic Breast Condition Market Competitive Landscape
• 30.2. Fibrocystic Breast Condition Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Hitachi Medical Systems Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Fibrocystic Breast Condition Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Siemens Healthineers AG
• 31.6. Fujifilm Holdings Corporation
• 31.7. Philips Healthcare
• 31.8. Becton Dickinson and Company
• 31.9. GE Healthcare Technologies Inc.
• 31.10. Teva Pharmaceutical Industries Ltd
• 31.11. Hologic Inc.
• 31.12. Canon Medical Systems Corporation
• 31.13. Hikma Pharmaceuticals plc
• 31.14. Steris Pharma
• 31.15. Lannett Company Inc.

32. Global Fibrocystic Breast Condition Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fibrocystic Breast Condition Market

34. Recent Developments In The Fibrocystic Breast Condition Market

35. Fibrocystic Breast Condition Market High Potential Countries, Segments and Strategies

• 35.1 Fibrocystic Breast Condition Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fibrocystic Breast Condition Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fibrocystic Breast Condition Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료